Article
Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region.
Emerging microbes & infections - 1 Dec 2021
Ma Pengjiao, Luo Tao, Ge Liang, Chen Zonghai, Wang Xinyan, Zhao Rongchuan, Liao Wei, Bao Lang
Abstract excerpt
Mycobacterium tuberculosis has been observed to develop resistance to the frontline anti-tuberculosis drug rifampicin, primarily through mutations in the rifampicin resistance-determining region (RRDR) of rpoB. While these mutations have been determined to confer a fitness cost, compensatory mutations in rpoA and rpoC that may enhance the fitness of resistant strains have been demonstrated. Recent genomic studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
